Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by SuperMoneyon Mar 30, 2018 9:55am
30 Views
Post# 27807734

RE:RE:RE:Great potentials

RE:RE:RE:Great potentialseSnowden, it seems you become more and more interested in ICO since your first post here in May 11, 2017. If ICO is a garbage as you said, why do you waste your time to stick on here recently? You said 10 years--Imnp fails to provide any updates to their trials for the drug. Really? Don't be fooling others. Just go to IMNP's website and read all the news/updates. Or go to ICO's website to read all the updates/presentation. Clearly, You are even not a shareholder. So no worry about ICO and go to play other penny stocks you like. Good luck.
eSnowden wrote:
Share price of ICO has less to do with luck & more to do with the current state of ICO. ICO-008 has been in phase 2 trials since 2008, 10 years--Imnp fails to provide any updates to their trials for the drug--& with Imnp valuation of $6million USD, it is safe to say that ICO-008 may be a failure. As far as ICO's lastest addition into their pipeline...results were pre-clinical, not even phase 1, much time & money for this one. With current finances expected to satisfy needs until Q2 this year, in reality ICO is in dire shape.


<< Previous
Bullboard Posts
Next >>